T3D
0.05
233.3%
PEN
0.33
-46.8%
GML
0.045
60.7%
RGL
0.003
-40%
ENT
0.008
60%
KLR
0.54
-34.1%
AIV
0.02
53.8%
JAV
0.002
-33.3%
QXR
0.006
50%
M2R
0.002
-33.3%
AQI
0.038
35.7%
RDS
0.004
-33.3%
NPM
0.018
28.6%
AOA
0.003
-25%
AHK
0.455
28.2%
BLZ
0.003
-25%
VML
0.165
26.9%
MEM
0.003
-25%
FIN
0.005
25%
LEG
0.007
-22.2%
VRC
0.005
25%
ADG
0.004
-20%
BCM
0.023
21.1%
CAV
0.004
-20%
FL1
0.12
20%
CVB
0.14
-20%
WHK
0.012
20%
FBR
0.004
-20%
S66
0.195
18.2%
IMI
0.008
-20%
KLS
4.76
18.1%
TRM
0.042
-19.2%
PAT
0.04
17.6%
GBE
0.06
-16.7%
NXL
2.41
17%
XGL
0.02
-16.7%
AJX
0.007
16.7%
ATV
0.016
-15.8%
AVE
0.007
16.7%
LU7
0.011
-15.4%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Cleo Diagnostics (ASX:COV): Bringing to market a simple blood test

Cleo Diagnostics (ASX:COV) is attempting to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide | Investor presentation: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02774453-3A636747